World TB Day 2022

Each year, we commemorate World Tuberculosis (TB) Day on March 24 to raise public awareness about the devastating health, social and economic consequences of TB, and to step up efforts to end the global TB epidemic. The date marks the day in 1882 when Dr Robert Koch announced that he had discovered the bacterium that causes TB, which opened the way towards diagnosing and curing this disease.

TB remains one of the world’s deadliest infectious killers. Each day, over 4100 people lose their lives to TB and close to 28,000 people fall ill with this preventable and curable disease. Global efforts to combat TB have saved an estimated 66 million lives since the year 2000. However, the COVID-19 pandemic has reversed years of progress made in the fight to end TB. For the first time in over a decade, TB deaths increased in 2020.

The theme of World TB Day 2022 – ‘Invest to End TB. Save Lives.’ –conveys the urgent need to invest resources to ramp up the fight against TB and achieve the commitments to end TB made by global leaders. This is especially critical in the context of the COVID-19 pandemic that has put End TB progress at risk, and to ensure equitable access to prevention and care in line with WHO’s drive towards achieving Universal Health Coverage.

More investment will save millions more lives, accelerating the end of the TB epidemic.



This year is a critical year for all of us in the global fight to end TB as we countdown to reach the UN High-Level Meeting (UNHLM) on TB targets which the international community agreed to meet by the end of December.

Ongoing COVID-19 efforts and a catastrophic funding gap of US$ 9 billion threatens to hamper global progress to combat TB. This is why we have chosen “Invest to End TB. Save Lives” as the theme for this year’s World TB Day campaign, which officially starts today.

The Stop TB Partnership and all partners are calling on all those involved in the fight against TB to unite under this overarching theme and sound the alarm that the low levels of funding for the TB response year after year cannot continue nor be accepted anymore. Of the US$ 15 billion annual funding for TB promised by world leaders at the UNHLM in 2018, less than half has been delivered. World leaders must step up and triple or quadruple the funding to save lives and end TB by 2030.


Moderna takes HIV trimer mRNA vaccine into clinical trials

The first participant has been dosed in a Phase 1 clinical trial of HIV trimer mRNA vaccine candidate mRNA-1574.


HIV-positive diagnosed in Estonia in 2022 (11.03.2022)

As of March 11, 2022, 18 HIV-infected persons have been diagnosed in Estonia.

Over the years, a total of 10,368 people have been diagnosed with the HIV virus in Estonia.


Help for LGBT+ refugees from Ukraine

Here you will find the main information about coming to Estonia if you are fleeing the war in Ukraine. Most of it is general, some LGBT+ specific. If you are an LGBT+ refugee from Ukraine and need any other help, please contact us at in English, Russian, or Estonian.

The information on this page will be updated as necessary.





All Ukrainian citizens can come to Estonia without a visa, including those without a biometric passport.

You can apply for international protection at the border or at a Police and Border Guard Board service point. The applicant has the right to stay in Estonia and will receive means of subsistence (accommodation, food, clothes, health services etc). Those who receive international protection will get a temporary residence permit and the right to work in Estonia. Applicants can live at the state-managed accommodation center or with relatives and friends who live in Estonia.

If you are not a citizen of Ukraine, the regular process of entering Estonia applies to you (visas, asylum applications, residence permits etc).

More information on the website and as PDF files in UkrainianRussianEnglish ja Estonian.


Currently it is possible to come to Estonia from Ukraine with a pet even if they do not fill the necessary requirements for travel (microchip/tattoo, rabies vaccination, documents). In that case you will need to fill out a form and send it to the Agriculture and Food Board and the Tax and Customs Board.

The form and contacts are here only in Estonian, but you can ask for help at the Estonian border crossing point.

Read more

Study of the project “Protection through Mobility: An Emergency Response to Hostility”

The project “Protection through Mobility: An Emergency Response to Hostility” was commissioned by the Estonian HIV-Positive Network
study on the implementation of humanitarian visa systems in the Member States of the European Union and the Schengen area.
A study has been ordered for this, with a file attached to it: EHPV_Study_Hum_Vis

HIV and Migration

1. Equal access to social medical services and uninterrupted HIV treatment for migrants in Estonia. As more and more people are coming to Estonia for work and study. For the last two years our organisation welcomed 30 migrants from different countries including HIV positive people and the representatives of vulnerable groups asking for support in getting social medical services as they were facing the following difficulties: 1 Access to medical services 2 Anxieties in terms of protecting confidentiality during the medical treatment 3 Language and cultural barriers 4 Access to testing, contraceptives, PReP and PEP, information on how to get the social medical services. Following its core mission and values, EHPV is providing full range of needed services. Connecting testing with treatment.

NGO Estonian Network of People Living with HIV wishes everyone a happy Valentine’s Day!

NGO Estonian Network of People Living with HIV wishes everyone a happy Valentine’s Day!

A highly virulent variant of HIV-1 circulating

Evolving virulence in HIV

Changes in viral load and CD4+ T cell decline are expected signals of HIV evolution. By examining data from well-characterized European cohorts, Wymant et al. report an exceptionally virulent subtype of HIV that has been circulating in the Netherlands for several years (see the Perspective by Wertheim). More than one hundred individuals infected with a characteristic subtype B lineage of HIV-1 were found who experienced double the rate of CD4+ cell count declines than expected. By the time they were diagnosed, these individuals were vulnerable to developing AIDS within 2 to 3 years. This virus lineage, which has apparently arisen de novo since around the millennium, shows extensive change across the genome affecting almost 300 amino acids, which makes it hard to discern the mechanism for elevated virulence. —CA


We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log10 increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV—CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences—is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.